NCT03283449CompletedPhase 1
Tau PET Imaging in Atypical Dementias
Source: ClinicalTrials.gov · Last updated 6 Apr 2025
Brief summary (registry, in English)
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 16 May 2016
- Start date
- 1 Feb 2016
- Primary completion date
- 28 Feb 2025
- Lead sponsor
- University of Chicago
- Diseases
- Frontotemporal dementia, Alzheimer disease
- NCT number
- NCT03283449
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 70
- From 1 Feb 2016 to the primary completion date, 28 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving radiation clinically
Other
- Pregnancy
- Breastfeeding
Who the study is looking for
- Must have primary progressive aphasia
Age in the registry: 20 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago - American School Building Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.